Interleukin-2 activation of cytotoxic cells in postmastectomy seroma

Journal of Surgical Research

Volumn 61, Issue 1, 1996, Pages 89-96

  Gercel Taylor, Cicek ^a   Huffman, John P ^b   Taylor, Douglas D ^a   Owens, Keith J ^a   Eisenberg, Burton L ^b  

^a University of Louisville School of Medicine   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL KILLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPOTENTIATION; LYMPHOCYTE ACTIVATION; MASTECTOMY; NATURAL KILLER CELL; PRIORITY JOURNAL; SEROMA;

EID: 0030056893     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1996.0086     Document Type: Article

References (22)

1. Longo, D. L., and Hartman, L. C. Biological response modifiers in the management of patients with breast cancer. Breast Cancer Res. and Treatment 16: 67, 1990.
2. Veronesi, U., Marubini, E., Del Vecchio, M. et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J. Natl. Cancer Inst. 87: 19-27, 1995.
3. Holland, R., Connolly, J. L., Gelman, R., et al. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J. Clin. Oncol. 8: 113-118, 1990.
4. Kurtz, J. M., Jacquemier, J., Amalric, R. et al. Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy. Cancer 65: 1867-1878, 1990.
5. Stotter, A. T., McNeese, M. D., Ames, F. C. et al. Predicting the rate and extent of locoregional failure after breast conservation therapy for early breast cancer. Cancer 64: 2217-2225, 1989.
6. Watt-Boolsen, S., Nielsen, V. B., Jensen, J., and Bak, S. Post-mastectomy seroma. Danish Medical Bulletin 37: 53, 1991.
7. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A. Lymphokine activated killer cell phenomenon. Lysis of natural killer-cell resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155: 1823, 1982.
8. Roberts, K., and Lotze, M. T., Rosenberg, S. A. Separation and functional studies of the human lymphokine-activated killer cells. Cancer Res. 47: 4366, 1987.
9. Fumita, Y., Tanaka, F., Saji, F., and Nakamuro, K. Immunosuppressive factors in ascites fluids from ovarian cancer patients. Am. J. Reprod. Immunol. Microbiol. 6: 175, 1984.
10. Guillou, P. J., Sedman, P. C., and Ramsden, C. W. Inhibition of lymphokine activated-killer cell generation by cultured tumor cell lines in vitro. Cancer Immunol. Immunother. 28: 43, 1989.
11. Hess, A. D., Gall, S. A., and Dawson, J. R. Inhibition of in vitro lymphocyte function by cystic and ascitic fluids from ovarian cancer patients. Cancer Res. 39: 2381, 1979.
12. Lichtenstein, A. K., Berek, J., and Zighelboim, J. Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer. J. Natl. Cancer Inst. 74: 349, 1985.
13. Phillips, J. H., and Lanier, L. L. Dissection of the lymphokine-activated phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J. Exp. Med. 164: 814, 1986.
14. Correale, P., Tagliaferri, P., Celio, L., Genua, G., Montagnani, S., and Bianco, A. R. Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytoxicity in vitro. Eur. J. Cancer 27: 1393, 1991.
15. Ramsdell, F. J., Shan, H., and Golub, S. H. Role of proliferation in LAK cell development. Cancer Immunol. Immunother. 26: 139, 1988.
16. Gercel-Taylor, C., Calaf, G., Hoffman, J. P., and Testa, J. R. Isolation of a malignant cell-line from post-mastectomy seroma. Proc. Amer. Assoc. Cancer Res. 33: 36, 1992.
17. Weil-Hillman, G., Fisch, P., Prieve, A. F., Sosman, J. A., Hank, J. A., and Sondel, P. M. Lymphokine-activated killer activity induced by in vivo interleukin-2 therapy: Predominant role for lymphocytes with increased expression of CD2 and Leu 19 antigens but negative expression of CD16 antigens. Cancer Res. 49: 3680, 1989.
18. Yagita, M., and Grimm, E. A. Current understanding of the lymphokine activated killer cell phenomenon. Prog. Exp. Tumor Res. 32: 213, 1988.
19. Itoh, K., Tilden, A. B., Kumagai, K., and Balch, C. M. Leu 11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL-2)-induced activated killer (AK) cells. J. Immunol. 134: 802, 1985.
20. Lanier, L. L., Le, A. H., Phillip, J. H., Warner, N. L., and Babcock, G. F. Subpopulations of human natural killer cells denned by expression of Leu-7 (HNK-1) and Leu-11 (NK-15) antigen. J. Immunol. 131: 1789, 1983.
21. Phillips, J. H., Gemlo, B. T., Meyers, W. W., Rayner, A. A., and Lanier, L. L. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J. Clin. Oncol. 5: 1933, 1987.
22. Timonen, T., Gahmberg, C. G., and Patarroyo, M. Participation of CD11a/CD18, CD2 and RGD-binding receptors in endogenous and interleukin-2 stimulated NK activity of CD3 negative large granular lymphocytes. Int. J. Cancer 46: 1035, 1990.